Exhibit 8.1
GROUP SUBSIDIARIES*
At December 31, 2024 |
| Country |
| Percentage of voting |
Wholly owned subsidiaries |
|
| ||
Alexion Pharmaceuticals, Inc. | United States | 100 | ||
Alexion Pharma Holding Limited | | Ireland | | 100 |
Alexion Pharma International Operations Limited Company | Ireland | 100 | ||
AstraZeneca AB | Sweden | 100 | ||
AstraZeneca Biotech AB | Sweden | 100 | ||
AstraZeneca Dunkerque Production SCS | France | 100 | ||
AstraZeneca Finance and Holdings Inc. | United States | 100 | ||
AstraZeneca Finance LLC | | United States | | 100 |
AstraZeneca Intermediate Holdings Limited | United Kingdom | 100 | ||
AstraZeneca Pharmaceuticals LP | | United States | | 100 |
AstraZeneca Treasury Limited | United Kingdom | 100 | ||
AstraZeneca UK Limited | United Kingdom | 100 | ||
MedImmune, LLC | United States | 100 | ||
Zeneca Holdings Inc. | | United States | | 100 |
* Subsidiary companies which would be deemed to be a “significant subsidiary” in accordance with rule 1-02(w) of Regulation S-X as at December 31, 2024.